MB Funds invests in Pharmatory, a Finnish contract development and manufacturing company (“CDMO”) specializing in small molecule active pharmaceutical ingredients (“APIs”), to support expansion of the company. The management of Pharmatory continues to develop the company in their current roles and as significant owners together with MB Funds.

Pharmatory, founded in 2001, provides services for global pharma and biotech companies in medicine development with CDMO offering for human and veterinary pharmaceuticals. The company’s service offering includes analytical, process R&D, and contract manufacturing services according to Good Manufacturing Practice (GMP). The company’s operations are based on long-term partnerships with its clients. Pharmatory has facility in Oulu, Finland, with a team of highly skilled and experienced professionals in the field of chemistry.  

“I’m happy to share an important milestone for Pharmatory. We truly welcome MB Funds as an investor and partner. This is more than a financial investment — it is a shared view on what we are building and where we are going. From the very first conversations it was clear that we aligned on vision, ambition, and values. With MB Funds’s experience and support, we are in a strong position to accelerate growth and create even more value for our clients. This investment represents a significant milestone on our 25-year-long journey, and we could not have chosen a better partner for the next phase. Pharmatory remains fully committed to delivering the exceptional quality and client experience in the future too. I’m grateful to everyone who has been part of getting us this far — the best still lies ahead”, states Dr. Jaana Karjalainen, CEO and a founding member of Pharmatory.

With the support of MB Funds, Pharmatory plans to expand its operations into rapidly growing high potency API (“HPAPI”) market by investing in HPAPI facility set-up.

“Pharmatory operates in a highly attractive small molecule API CDMO market and holds a reputation for high scientific know-how, agile client-centric services, quality and effective project management. The company has very capable management with strong experience from international operations and an organization with deep chemistry expertise. Pharmatory is well-positioned to expand into sizeable and rapidly growing high potency API CDMO market, supported by very robust underlying trends, and MB Funds is excited to support company’s growth”, comments Anssi Mattila, partner of MB Funds.

“The investment will focus on construction of a new manufacturing area along with the supporting infrastructure within the existing industrial premises. This enables us to offer a broader spectrum of services, especially for the high potency API GMP manufacturing market, in the near future.

The entire Pharmatory team is excited, and we are confident that this collaboration will bring clear benefits to our clients and further enhance the services they have come to rely on over the years. The partnership with MB Funds and the new board members strengthen our journey and give us great support for our next phase of growth”, comments Dr. Heikki Hassila, Business Development Director of Pharmatory.

Pharmatory’s board will be strengthened by Dr. Knut Ringbom, former CEO and one of the founders of Biovian, and Arto Toivonen, M.Sc. (Chem.Eng.), former President of Fermion and Business Development Director of Orion. Ringbom and Toivonen will also become shareholders of Pharmatory together with the management and MB Funds. Anssi Mattila serves as Chair of the Board of Pharmatory, and the other members are Meri Koivula, Knut Ringblom and Arto Toivonen.

Further information:
Anssi Mattila
Partner, MB Funds
+358 50 538 5806 or anssi.mattila@mb.fi

Jaana Karjalainen
CEO, Pharmatory Oy
+358 44 270 7271 or jaana.karjalainen@pharmatory.com                                                            

Pharmatory briefly
Pharmatory, founded in 2001, is a Finnish contract development and manufacturing company (CDMO) specializing in small molecule active pharmaceutical ingredients (APIs). The company supports pharma and biotech companies in medicine development with CDMO offering that includes analytical, process R&D and contract manufacturing services for human and veterinary pharmaceuticals. Pharmatory operates both with new chemical entities (NCEs) and generic market compounds according to Good Manufacturing Practice (GMP) standards. Pharmatory’s facility in Oulu, Finland, is inspected by the European Medicines Agency (EMA/FIMEA) and regularly by its partners and clients.

www.pharmatory.com

MB Funds briefly
MB Funds is the leading Finnish private equity investor founded in 1988. Total assets under MB Funds management stand at 0.5 billion euro with prime Finnish institutions as its main fund investors. MB Funds has successfully invested in more than 50 mid-sized companies in the Nordics.

www.mb.fi

This year marks 25 years since our journey began.

For 25 years, we’ve been proud to support the pharmaceutical industry with high-quality API services built on trust and expertise. We’ve had the privilege of working with great people, solving real problems, and growing together with our customers.

What started as a focused vision has grown into long-term partnerships, global collaboration, and a shared commitment to improving patient outcomes. None of this would be possible without our dedicated highly skilful teams, trusted customers, and valued partners. A huge thank you to our employees, customers, and partners who made this possible.

As we celebrate this milestone, we’re not just looking back — we’re looking forward. The next chapter is about innovation, sustainability, and continuing to deliver new reliable CDMO services and solutions in an ever-evolving industry.

Thank you for being part of our journey.
The future of pharma is being built now — and we’re ready for it. We are proud of what we’ve built together and excited about what lies ahead.

The past 25 years shaped us. The next ones will define us.

With the remaining days of the year 2025 slowly getting fewer and fewer, it is time to sit back for a while and reflect back on the past year. The whole Pharmatory team had an opportunity to gather together, celebrate the busy but successful year over a great dinner in a local restaurant and take time for some informal discussion. Deepest thanks to every member of the team for the year and let’s make the new year 2026 even more fruitful one together!

The CPhI 2025 in Frankfurt, Germany, was again filled with walking and meeting with collaboration partners existing and new. We thank everyone we had the pleasure to interact with and look forward to seeing you all soon again!

Pharmatory has recently expanded the office facilities with a new, modern lunch space and a fully equipped meeting room.

After the cool and rainy June, Finland was able to enjoy real summer weather with sunshine and temperatures raising above 30°C for 20 consecutive days, which marks a historical record. On July 31st Oulu was the hottest place in Finland, almost 33°C.

After the heat wave we have now returned back to the usual August figures and activities in the office and labs are also regaining momentum after the holiday season. At the same time we are making concrete moves towards the events of the fall season. On the current list are CPhI Europe in Frankfurt, Germany, on October 28th-30th and BioEurope 2025 in Vienna, Austria, on November 3rd-5th. We look forward to seeing you there, please get in touch to fix a meeting!

Pharmatory has been awarded the certificate ‘Strongest in Finland Platinum’ for the 9th consecutive year.

Strongest in Finland certificate tells customers, partners, lenders and other stakeholders that the cooperation with the company is on a solid ground. The certificate enables the company to stand out from its competitors, attract positive attention and strengthen its brand image. Strongest in Finland is a certificate of good governance. Sustainability (ESG) and its reporting has become a permanent part of companies’ obligations and practices. Asiakastieto’s ESG Report lists the company’s certifications from various external sources. The mention of the Finnish Strongest certificate is automatically displayed in the good governance column and is a sign of a well-managed company.

3 % of all FInnish companies are qualified for Platinum certification.

We just returned back home after attending the annual DCAT Week assembly in New York.

Attending for the first time, we found the event very successful with many encounters, both prearranged and spontaneous, with people we otherwise might have not been able to meet with. Great discussions and exchanges of thoughts and ideas in an inspiring and welcoming atmosphere, where everyone was free to meet and greet everyone else. The organized talks and sessions were also very practical and informative, covering many aspects of the pharmaceutical industry and its development in the contemporary world.

Thank you very much again for everyone we had the honor to meet, we will take everything with us and carry on forward empowered by the meetings. We look forward to seeing you all again in March 2026!